- Home
- RS vs IKT Comparison
RS vs IKT Comparison
Compare RS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RS
- IKT
- Stock Information
- Founded
- RS 1939
- IKT 2008
- Country
- RS United States
- IKT United States
- Employees
- RS N/A
- IKT N/A
- Industry
- RS Metal Fabrications
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- RS Industrials
- IKT Health Care
- Exchange
- RS Nasdaq
- IKT Nasdaq
- Market Cap
- RS 17.9B
- IKT 140.5M
- IPO Year
- RS 1994
- IKT 2020
- Fundamental
- Price
- RS $288.27
- IKT $1.57
- Analyst Decision
- RS Buy
- IKT Buy
- Analyst Count
- RS 5
- IKT 2
- Target Price
- RS $328.80
- IKT $8.00
- AVG Volume (30 Days)
- RS 267.2K
- IKT 92.1K
- Earning Date
- RS 10-22-2025
- IKT 11-13-2025
- Dividend Yield
- RS 1.65%
- IKT N/A
- EPS Growth
- RS N/A
- IKT N/A
- EPS
- RS 13.66
- IKT N/A
- Revenue
- RS $13,691,400,000.00
- IKT N/A
- Revenue This Year
- RS $4.70
- IKT N/A
- Revenue Next Year
- RS $4.29
- IKT N/A
- P/E Ratio
- RS $21.25
- IKT N/A
- Revenue Growth
- RS N/A
- IKT N/A
- 52 Week Low
- RS $250.07
- IKT $1.12
- 52 Week High
- RS $347.44
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- RS 42.60
- IKT 43.17
- Support Level
- RS $288.55
- IKT $1.50
- Resistance Level
- RS $298.61
- IKT $1.73
- Average True Range (ATR)
- RS 6.17
- IKT 0.09
- MACD
- RS -0.01
- IKT -0.02
- Stochastic Oscillator
- RS 5.80
- IKT 20.05
About RS Reliance Steel & Aluminum Co. (DE)
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.